Treatment of pancreatic CAFs with all-trans retinoic acid (ATRA) reduces expression of αSMA and FAP, decreases the production of ECM, reduces the expression and secretion of IL-6, and results in CAF-mediated reduction of migration and EMT in the tumor cells [514]. The gene discussed is ACTA1; the disease is neoplasm.